Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 71 of 95, showing 5 Applications out of 471 total, starting on record 351, ending on 355

# Protocol No Study Title Investigator(s) & Site(s)

351.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View

352.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

353.

ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants       
Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
 
View

354.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
View

355.

ECCT/16/02/05   PfSPZ Malaria Vaccine
    Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy   
Principal Investigator(s)
1. Martina Oneko
2. Mary J Hamel
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Wagai Health Center (Siaya county)
 
View